IQVIA Holdings Inc
NYSE:IQV

Watchlist Manager
IQVIA Holdings Inc Logo
IQVIA Holdings Inc
NYSE:IQV
Watchlist
Price: 201.82 USD 2.14% Market Closed
Market Cap: 36.7B USD
Have any thoughts about
IQVIA Holdings Inc?
Write Note

IQVIA Holdings Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IQVIA Holdings Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
IQVIA Holdings Inc
NYSE:IQV
Total Receivables
$3.3B
CAGR 3-Years
11%
CAGR 5-Years
5%
CAGR 10-Years
12%
Thermo Fisher Scientific Inc
NYSE:TMO
Total Receivables
$9.8B
CAGR 3-Years
15%
CAGR 5-Years
17%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
Total Receivables
$4.1B
CAGR 3-Years
-1%
CAGR 5-Years
3%
CAGR 10-Years
2%
West Pharmaceutical Services Inc
NYSE:WST
Total Receivables
$524.3m
CAGR 3-Years
3%
CAGR 5-Years
11%
CAGR 10-Years
10%
Mettler-Toledo International Inc
NYSE:MTD
Total Receivables
$637.2m
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Total Receivables
$1.2B
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
3%
No Stocks Found

IQVIA Holdings Inc
Glance View

Market Cap
36.7B USD
Industry
Life Sciences Tools & Services

IQVIA Holdings Inc. stands at the crossroads of healthcare and technology, blending innovative data analytics with deep industry expertise to enhance the clinical development and commercialization of pharmaceuticals. Founded in 2016 from the merger of IMS Health and Quintiles, IQVIA has rapidly positioned itself as a leader within the life sciences sector. The company's core mission revolves around leveraging vast sources of healthcare data and advanced artificial intelligence to provide actionable insights, streamline drug development processes, and facilitate improved patient outcomes. With a global footprint extending across more than 100 countries, IQVIA serves a diverse clientele, including biopharmaceutical companies, healthcare providers, and government organizations, making it a pivotal player in the ever-evolving healthcare landscape. For investors, IQVIA represents a compelling opportunity that combines robust financial performance with strong market demand driven by the growing complexities of drug development and regulatory environments. As the healthcare sector increasingly turns to data-driven decision-making, IQVIA's extensive suite of services—including real-world evidence, market access solutions, and technology-enabled clinical trial services—positions it favorably in a market ripe for innovation. The company's commitment to research and development, coupled with strategic partnerships and acquisitions, fuels its long-term growth trajectory. Furthermore, IQVIA's resilience in navigating industry shifts, highlighted by its consistent revenue growth and healthy profit margins, reflects a business model that is not only scalable but also agile enough to adapt to the challenges and opportunities of modern medicine.

IQV Intrinsic Value
259.71 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is IQVIA Holdings Inc's Total Receivables?
Total Receivables
3.3B USD

Based on the financial report for Sep 30, 2024, IQVIA Holdings Inc's Total Receivables amounts to 3.3B USD.

What is IQVIA Holdings Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
12%

Over the last year, the Total Receivables growth was -1%. The average annual Total Receivables growth rates for IQVIA Holdings Inc have been 11% over the past three years , 5% over the past five years , and 12% over the past ten years .

Back to Top